---
title: "KLRS.US (KLRS.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KLRS.US/news.md"
symbol: "KLRS.US"
name: "KLRS.US"
parent: "https://longbridge.com/en/quote/KLRS.US.md"
datetime: "2026-03-04T13:08:55.718Z"
locales:
  - [en](https://longbridge.com/en/quote/KLRS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KLRS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KLRS.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/KLRS.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/KLRS.US/news.md)


# KLRS.US (KLRS.US) — Related News

### [Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Increases By 60.8%](https://longbridge.com/en/news/274403871.md)
*2026-02-01T03:14:03.000Z*
> Kalaris Therapeutics Inc. (NASDAQ:KLRS) experienced a significant increase in short interest, rising 60.8% to 867,767 sh

### [Kalaris Therapeutics Unveils Phase 1 Data for TH103 in Neovascular AMD at Macula Society Meeting](https://longbridge.com/en/news/274041517.md)
*2026-01-28T21:05:35.000Z*
> Kalaris Therapeutics Inc. will present Phase 1 clinical data for TH103, a dual-targeting VEGF and HSPG inhibitor, at the

### [Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1%](https://longbridge.com/en/news/271201887.md)
*2025-12-31T10:18:41.000Z*
> Kalaris Therapeutics Inc. (NASDAQ:KLRS) experienced a 26.1% increase in short interest in December, totaling 503,479 sha

### [Early Clinical Strength and Durability of TH103 Underpin Buy Rating on Kalaris Therapeutics](https://longbridge.com/en/news/270591231.md)
*2025-12-23T08:45:23.000Z*
> William Blair analyst Lachlan Hanbury Brown maintains a Buy rating on KLRS stock due to the promising early clinical per

### [Kalaris Therapeutics raised $50M in an oversubscribed private placement to develop treatments for retinal diseases.](https://longbridge.com/en/news/270382728.md)
*2025-12-20T13:30:07.000Z*
> On December 17, 2025, Kalaris Therapeutics, Inc. disclosed that they have collaborated with a group of accredited invest

### [U.S. stock market midday update: Private equity financing raises dilution concerns, Kalaris Therapeutics stock price plummets 11.52%](https://longbridge.com/en/news/270346044.md)
*2025-12-19T19:32:51.000Z*
> Kalaris Therapeutics fell 11.52%; Aime Medical rose 30.44%, with a transaction volume of USD 2.23 billion; AbbVie rose 1

### [Piper Sandler Reaffirms Their Hold Rating on Kalaris Therapeutics (KLRS)](https://longbridge.com/en/news/270164240.md)
*2025-12-18T13:05:31.000Z*
> Piper Sandler analyst Biren Amin maintained a Hold rating on Kalaris Therapeutics, setting a price target of $5.00. Amin

### [Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement | KLRS Stock News](https://longbridge.com/en/news/270073228.md)
*2025-12-17T14:59:00.000Z*
> Kalaris Therapeutics, a clinical-stage biopharmaceutical company, announced a $50 million private placement with institu